The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation

The purpose of this study is to assess if radiation therapy (which uses high-energy radiation to damage or destroy cancer cells) combined with immune checkpoint inhibitors (medications that helps the body recognize and attack cancer cells) will be beneficial for patients with metastatic pancreatic ductal adenocarcinoma.

Trial Details

NCT ID
NCT06843551
Phase
PHASE2
Sponsor
Benjamin Spieler
Status
RECRUITING
Cancer Type
Pancreatic Ductal Adenocarcinoma Pancreatic Cancer
Interventions
  • Stereotactic Body Radiation Therapy
  • Botensilimab
  • Balstilimab
Locations (sample)
  • Miami, Florida, United States|25.77427,-80.19366

Key Eligibility Criteria

  • ≥18 years old
  • Histologically or cytologically confirmed diagnosis of pancreatic ductal adenocarcinoma.
  • Microsatellite stable (MSS) disease by pathologic assessment.
  • Patients must have measurable disease as defined by RECIST 1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Ductal Adenocarcinoma Pancreatic Cancer Trials on Trialify →